Roslyn Tedja, PhD

Assistant Professor, Department of Obstetrics and Gynecology, Wayne State University; Member, Tumor Biology and Microenvironment, Barbara Ann Karmanos Cancer Institute

Dr. Tedja received her PhD in Chemical Engineering and B.Sc. in Biotechnology (Hons.) from University of New South Wales, Sydney, Australia. Her first post-doctoral position was in the Cancer Therapeutic company, EnGeneIC, her work aimed to investigate the immunological effects of nanocell platform used for targeted delivery of chemotherapeutics and functional nucleic acid in cancer. She then joined a plasma therapeutic company Prime Biologic. Afterwards, she joined Dr. Gil Mor’s laboratory at the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine for a post-doctoral fellowship and focused her work in ovarian cancer metastasis. Dr. Tedja’s research focuses in 1) identifying early molecular changes that govern the initiation of epithelial-to-mesenchymal transition (EMT) in ovarian cancer progression, metastasis and recurrence, and 2) developing novel delivery platform of chemotherapeutics to target residual disease.

• Paper accepted April 17, 2020 in the journal Oncoimmunology: “Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer” by Ayesha B. Alvero, Douglas Hanlon, Mary Pitruzzello, Renata Filler, Eve Robinson, Olga Sobolev, Roslyn Tedja, Alessandra Ventura, Patrick Han, Marcus Bosenberg, Richard Edelson, and Gil Mor.
• Paper accepted March 5, 2020 in the journal Oncogene: “CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential” by Juanni Li, Ayesha B. Alvero, Sudhakar Nut, Roslyn Tedja, Cai Roberts, Mary Pitruzzello, Yimin Li, Qing Xiao, Sai Zhang, Yaqi Gan, Xiaoying Wu, Gil Mor, and Gang Yin.

1. Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Edelson R, Mor G.  Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology, 2020.

2. Li J, Alvero AB, Nuti S, Tedja R, Roberts CM, Pitruzzello M, Li Y, Xiao Q, Zhang S, Gan Y, Wu X, Mor G, Yin G. CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. Oncogene, 2020.

3. Robert CM, Cardenas C, Tedja R. The role of intra-tumoral heterogeneity and its clinical relevance in epithelial ovarian cancer recurrence and metastasis. 2019. Cancers. 11(8), 1083.

4. Tedja R, Roberts C, Alvero AB, Cardenas C, Yang-Hartwich Y, Spadinger S, Pitruzzello M, Yin, G, Glackin CA, Mor G. Phosphorylation of Twist1 Serine144 by protein kinase C aplha contribute to its stable expression. Journal of Biological Chemistry, 2019; 294(13):5082-5093.

5. Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, Cardenas C, Gurrea-Soteras M, Sumi N, Alvero AB, Glackin C, and Mor G. p53-Pirh2 complex promotes Twist1 degradation and inhibits EMT in ovarian cancer cells. Mol Cancer Res, 2019; 17(1):153-164.